Ability Pharma: Ability Pharma Receives 2 Million From the Government for Its Cancer Treatment

Ability Pharma is working on a drug capable of inducing cancer cell death through autophagy. ABTL0812 has demonstrated clinical efficacy in a Phase II clinical trial in patients with endometrial cancer or non-small cell lung cancer, as first-line treatment in combination with chemotherapy and as maintenance treatment after chemotherapy cycles.